Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.46 |
| ▸ | FEN1 | P39748 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | NQO2 | P16083 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764957 | 0.87 | PDE4D (0.42) | ADORA1NQO2MCHR1ADORA2APDGFRB | |
| SCHEMBL20765242 | 0.86 | NPC1 (0.51) | SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL22634416 | 0.86 | FYN (0.49) | ALOX5APFEN1ADORA1MCHR1ADORA2A | |
| SCHEMBL22634327 | 0.86 | P2RX3 (0.44) | ALOX5APFEN1METMCHR1P2RX3 | |
| SCHEMBL22634332 | 0.84 | FYN (0.49) | ALOX5APFEN1ADORA1MCHR1FYN | |
| SCHEMBL22634432 | 0.83 | NQO2 (0.42) | ALOX5APFEN1NQO2MCHR1ADORA2A | |
| SCHEMBL22634408 | 0.82 | ALOX5AP (0.45) | ALOX5APFEN1NQO2MCHR1IDO1 | |
| SCHEMBL22634400 | 0.82 | SMN1; SMN2 (0.44) | NQO2MCHR1ADORA2AKMT2AMAPT | |
| SCHEMBL20765238 | 0.79 | ADORA1 (0.45) | ADORA1MCHR1ADORA2AP2RX3P2RX2 | |
| SCHEMBL30439469 | 0.79 | MAPT (0.48) | ALOX5APFEN1ADORA1METADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192899-B2 | Quinoxaline derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-12-07 | — | — | US | claimed |
| US-20200354375-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-11-12 | — | — | US | claimed |
| CN-110944994-A | Quinoxaline derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2020-03-31 | — | — | CN | claimed |
| EP-3672951-B1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-11192899-B2 | Quinoxaline derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-12-07 | — | — | US | disclosed |
| US-11192899-B2 | Quinoxaline derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-12-07 | — | — | US | disclosed |
| US-20200354375-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-11-12 | — | — | US | disclosed |
| US-20200354375-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-11-12 | — | — | US | disclosed |
| EP-3672951-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| CN-110944994-A | Quinoxaline derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2020-03-31 | — | — | CN | disclosed |
| WO-2019038214-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354375-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, P2RY1 | ALOX5AP 1071/4885FEN1 447/4885ADORA1 2/4885 |
| US-11192899-B2 | Quinoxaline derivatives as adenosine receptor antagonists | ADORA2A, ADORA1, P2RY1 | ALOX5AP 1071/4885FEN1 447/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.